Abstract

BackgroundIschemic stroke is one of the main causes of death and disability worldwide. It is caused by the cessation of cerebral blood flow resulting in the insufficient delivery of glucose and oxygen to the neural tissue. The inflammatory response initiated by ischemic stroke in order to restore tissue homeostasis in the acute phase of stroke contributes to delayed brain damage.MethodsBy using in vitro models of neuroinflammation and in vivo model of permanent middle cerebral artery occlusion, we demonstrate the neuroprotective and anti-inflammatory effects of sulfosuccinimidyl oleate sodium (SSO).ResultsSSO significantly reduced the lipopolysaccharide/interferon-γ-induced production of nitric oxide, interleukin-6 and tumor necrosis factor-α, and the protein levels of inflammatory enzymes including nitric oxide synthase 2, cyclooxygenase-2 (COX-2), and p38 mitogen-activated protein kinase (MAPK) in microglia, without causing cell toxicity. Although SSO failed to directly alleviate glutamate-induced excitotoxicity in murine cortical neurons, it prevented inflammation-induced neuronal death in microglia-neuron co-cultures. Importantly, oral administration of SSO in Balb/c mice subjected to permanent occlusion of the middle cerebral artery reduced microglial activation in the peri-ischemic area and attenuated brain damage. This in vivo neuroprotective effect of SSO was associated with a reduction in the COX-2 and heme oxygenase-1 immunoreactivities.ConclusionsOur results suggest that SSO is an anti-inflammatory and a possible therapeutic candidate in diseases such as stroke where inflammation is a central hallmark.

Highlights

  • Ischemic stroke is one of the main causes of death and disability worldwide

  • LPS binds to Toll-like receptors (TLRs), such as TLR4, and initiates the activation of the p38 mitogen-activated protein kinase (MAPK) and Nuclear factor kappa-B (NFκB) pathway resulting in the production of NOS2, Nitric oxide (NO), and various a g

  • Microglia play a prominent role in regulating strokeinduced inflammation

Read more

Summary

Introduction

Ischemic stroke is one of the main causes of death and disability worldwide. It is caused by the cessation of cerebral blood flow resulting in the insufficient delivery of glucose and oxygen to the neural tissue. The inflammatory response initiated by ischemic stroke in order to restore tissue homeostasis in the acute phase of stroke contributes to delayed brain damage. Brain inflammation is mediated by microglia, astrocytes, and infiltrating peripheral leukocytes, primarily neutrophils and monocytes [3]. These inflammatory cells produce a variety of cytotoxic molecules, including pro-inflammatory. (TGF-β) are involved in the resolution of inflammation [2] Drugs, such as curcumin [6] and minocycline [7, 8], that alleviate inflammatory reactions have been shown to reduce ischemic damage and aid in functional recovery in preclinical models of stroke. Despite the lack of translational success and efficacy of anti-inflammatory agents far in human stroke [9, 10], modulation of microglial activation still holds promise in the treatment of stroke

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call